Drugs / GATRALIMAB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02977533 | Dec 2016 → May 2018 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02282826 | Oct 2014 → Mar 2016 | multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GATRALIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068609 ↗ |
| Known as | GZ402668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02977533 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068609 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT02282826 ↗ |